Abstract
INFLIXIMAB is A CHIMERIC ANTI-TUMOUR NECROSIS FACTOR-α antibody that is efficacious in treating Crohn's disease. However, its immunomodulatory properties increase susceptibility to opportunistic infections. We present a case of cutaneous Nocardia infection in a patient who was taking infliximab for Crohn's disease. The case illustrates the challenges in the diagnosis and management of this disease and serves as a reminder of the complications associated with the use of immunomodulatory agents.
Cite
CITATION STYLE
Singh, S. M., Rau, N. V., Cohen, L. B., & Harris, H. (2004). Cutaneous nocardiosis complicating management of Crohn’s disease with infliximab and prednisone. CMAJ. Canadian Medical Association Journal, 171(9), 1063–1064. https://doi.org/10.1503/cmaj.1040563
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
